Gabriel Vallecillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gabriel Vallecillo has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Marta Torrens
Drug Addiction Program Instituto de Neuropsiquiatría y Adicciones Barcelona Spain
5 shared publications- Roberto Muga
Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Badalona, Spain
4 shared publications Albert Roquer
Institute of Neuropsychiatry and Addictions Hospital del Mar Barcelona Spain
3 shared publications- Arantza Sanvisens
Integrated Cancer Registries Service (SIRC), Catalan Institute of Oncology, 17007 Girona, Spain
2 shared publications - Hernando Knobel
Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain
2 shared publications Josep M. Llibre
2 shared publications
Latest Publications
- 6 June 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 41 (6) , 1311-1318
COVID‐19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain
Introduction: People with substance use disorders are considered a priority group for SARS‐CoV‐2 vaccination as they are at elevated risk of COVID‐19 and its severe complications. However, data are scarce about vaccination coverage in a real‐world setting.Methods: A descriptive study was conducted in people with opioid use disorder (OUD) from three public centres for outpatient drug addiction treatment in Barcelona, Spain, who received brief medical advice and were referred to vaccination clinic sites.Results: Three hundred and sixty‐two individuals were included: 277 (77%) were men with a mean age of 48.1 ± 8.9 years and 77% were Spanish. Most (90%) participants engaged in polysubstance use and all individuals were on opioid agonist therapy. Psychiatric comorbidity was present in 56% subjects and 32% individuals had ≥1 chronic disease, 30% had HIV and 13% hepatitis C. There were 258 fully vaccinated individuals (71%; 95% confidence interval [CI] 67, 76). Age (odds ratio [OR] 1.04; 95% CI 1.01, 1.08; P < 0.01) and Charlson Comorbidity Index (OR 1.67; 95% CI 1.11, 2.5; P < 0.01) were associated with full vaccination. The vaccination hesitancy causes cited were complacency (53, 51%), convenience (40, 39%) and confidence (11, 10%).Discussion and Conclusions: More than two‐thirds of our sample of people with OUD were fully vaccinated. Complacency and convenience represented a significant barrier to complete vaccination among people with OUD on opioid agonist therapy referred to vaccination clinic sites. Additional measures are necessary to increase vaccination, especially for younger individuals and those with less medical comorbidity. Integrating vaccination services in drug outpatient centres could be a useful alternative.
- 6 June 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 41 (6) , 1311-1318
COVID‐19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain
Introduction: People with substance use disorders are considered a priority group for SARS‐CoV‐2 vaccination as they are at elevated risk of COVID‐19 and its severe complications. However, data are scarce about vaccination coverage in a real‐world setting.Methods: A descriptive study was conducted in people with opioid use disorder (OUD) from three public centres for outpatient drug addiction treatment in Barcelona, Spain, who received brief medical advice and were referred to vaccination clinic sites.Results: Three hundred and sixty‐two individuals were included: 277 (77%) were men with a mean age of 48.1 ± 8.9 years and 77% were Spanish. Most (90%) participants engaged in polysubstance use and all individuals were on opioid agonist therapy. Psychiatric comorbidity was present in 56% subjects and 32% individuals had ≥1 chronic disease, 30% had HIV and 13% hepatitis C. There were 258 fully vaccinated individuals (71%; 95% confidence interval [CI] 67, 76). Age (odds ratio [OR] 1.04; 95% CI 1.01, 1.08; P < 0.01) and Charlson Comorbidity Index (OR 1.67; 95% CI 1.11, 2.5; P < 0.01) were associated with full vaccination. The vaccination hesitancy causes cited were complacency (53, 51%), convenience (40, 39%) and confidence (11, 10%).Discussion and Conclusions: More than two‐thirds of our sample of people with OUD were fully vaccinated. Complacency and convenience represented a significant barrier to complete vaccination among people with OUD on opioid agonist therapy referred to vaccination clinic sites. Additional measures are necessary to increase vaccination, especially for younger individuals and those with less medical comorbidity. Integrating vaccination services in drug outpatient centres could be a useful alternative.
- 17 February 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 41 (5) , 1078-1084
High cardiovascular risk in older patients with opioid use disorder: Differences with the general population
Introduction: Cardiovascular disease is a health concern in ageing population with opioid use disorders (OUD). The study aims to analyse the cardiovascular risk factors in individuals with OUD.Methods: An observational study was carried out to compare cardiovascular risk factors of adults >50 years with OUD on methadone therapy from public outpatient drug treatment centres, with that of an age‐ and gender‐matched sample (ratio of 1:5) of subjects from a sample of the Spanish population (REGICOR cohort). High cardiovascular risk (HCVR) at 10 years was defined according to Framingham‐REGICOR and SCORE risk functions.Results: The individuals studied included 94 people with OUD and 495 from the general population; the mean age was 55.7 ± 4.8 years and 432 (72.7%) were men. Obesity (21.2% vs. 35.2%), hypertension (26.3% vs. 42.1%), total cholesterol (30.3% vs. 65.4%) and LDL‐cholesterol ≥130 mg/dL (27.2% vs. 59.3%) were significantly more prevalent in the general population group, while tobacco smoking (96.0% vs. 25.9%), low HDL‐cholesterol (46.5% vs. 21.2%), hypertriglyceridaemia (39.4% vs. 18.8%) and atherogenic dyslipidaemia (30.3% vs. 10.5%) were significantly higher in individuals with OUD. Differences in abdominal obesity (62.6% vs. 65.3%) were not significant. HCVR was more prevalent in patients with OUD: 15.2% versus 5.8% (Framingham‐REGICOR function) and 21.2% versus 11.3% (SCORE function).Discussion and Conclusions: Older adults with OUD on methadone therapy have a different prevalence of cardiovascular risk factors and HCVR than the general population. Preventive measures, particularly tobacco smoking cessation and weight control, should be included in the routine care of individuals with OUD.
- 17 February 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 41 (5) , 1078-1084
High cardiovascular risk in older patients with opioid use disorder: Differences with the general population
Introduction: Cardiovascular disease is a health concern in ageing population with opioid use disorders (OUD). The study aims to analyse the cardiovascular risk factors in individuals with OUD.Methods: An observational study was carried out to compare cardiovascular risk factors of adults >50 years with OUD on methadone therapy from public outpatient drug treatment centres, with that of an age‐ and gender‐matched sample (ratio of 1:5) of subjects from a sample of the Spanish population (REGICOR cohort). High cardiovascular risk (HCVR) at 10 years was defined according to Framingham‐REGICOR and SCORE risk functions.Results: The individuals studied included 94 people with OUD and 495 from the general population; the mean age was 55.7 ± 4.8 years and 432 (72.7%) were men. Obesity (21.2% vs. 35.2%), hypertension (26.3% vs. 42.1%), total cholesterol (30.3% vs. 65.4%) and LDL‐cholesterol ≥130 mg/dL (27.2% vs. 59.3%) were significantly more prevalent in the general population group, while tobacco smoking (96.0% vs. 25.9%), low HDL‐cholesterol (46.5% vs. 21.2%), hypertriglyceridaemia (39.4% vs. 18.8%) and atherogenic dyslipidaemia (30.3% vs. 10.5%) were significantly higher in individuals with OUD. Differences in abdominal obesity (62.6% vs. 65.3%) were not significant. HCVR was more prevalent in patients with OUD: 15.2% versus 5.8% (Framingham‐REGICOR function) and 21.2% versus 11.3% (SCORE function).Discussion and Conclusions: Older adults with OUD on methadone therapy have a different prevalence of cardiovascular risk factors and HCVR than the general population. Preventive measures, particularly tobacco smoking cessation and weight control, should be included in the routine care of individuals with OUD.
- 1 March 2021
- Published by Elsevier in Geriatric Nursing
- Vol. 42 (2) , 544-547
Effectiveness of an Acute Care for Elders unit at a long-term care facility for frail older patients with COVID-19
- 1 March 2021
- Published by Elsevier in Geriatric Nursing
- Vol. 42 (2) , 544-547
Effectiveness of an Acute Care for Elders unit at a long-term care facility for frail older patients with COVID-19
- Open Access
- 11 December 2020
- Published by Peertechz Publications Private Limited in Archive of Gerontology and Geriatrics Research
- Vol. 5 (1) , 043-047
Impact of a COVID-19 outbreak in a long-term care facility in Barcelona, Spain: The role of a COVID-19 prevention and control program
- 11 December 2020
- Published by Peertechz Publications Private Limited in Archive of Gerontology and Geriatrics Research
- Vol. 5 (1) , 043-047
Open AccessImpact of a COVID-19 outbreak in a long-term care facility in Barcelona, Spain: The role of a COVID-19 prevention and control program
- Open Access
- 26 October 2020
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 43 (1) , 9-12
Clinical impact of COVID-19 on people with substance use disorders
Background: People with substance use disorders are considered at increased risk of COVID-19 and its more serious complications, however data on the impact of COVID-19 are lacking. The study aimed to describe the clinical characteristics and outcomes of COVID-19 on people with substance use disorders. Methods: an observational study was carried out including patients aged ≥ years with COVID-19 pneumonia admitted to an urban hospital during March 12 to June 21,2020. Results: Among 2078 patients admitted, 27 (1.3%) were people with substance use disorders: 23(85.2%) were men with a median age of 56.1 + 10.3 years and. The main SUD were alcohol in 18(66.7%) patients, heroine in 6(22.2%) and cocaine in 3(11.1%) and 24(88.8%) patients were on ongoing substance use disorder treatment. One or more comorbidities associated to COVID-19 risk were observed in 18(66.6%) of patients. During a median length of stay of 10 days (IQR:7-19), severe pneumonia developed in 7(25.9%) patients, acute respiratory distress syndrome in 5 (18.5%) and none died. Conclusion: Larger sample sizes and sero-epidemiological studies are needed to confirm the low incidence of severe COVID-19 on patients with SUD.
- 26 October 2020
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 43 (1) , 9-12
Open AccessClinical impact of COVID-19 on people with substance use disorders
Background: People with substance use disorders are considered at increased risk of COVID-19 and its more serious complications, however data on the impact of COVID-19 are lacking. The study aimed to describe the clinical characteristics and outcomes of COVID-19 on people with substance use disorders. Methods: an observational study was carried out including patients aged ≥ years with COVID-19 pneumonia admitted to an urban hospital during March 12 to June 21,2020. Results: Among 2078 patients admitted, 27 (1.3%) were people with substance use disorders: 23(85.2%) were men with a median age of 56.1 + 10.3 years and. The main SUD were alcohol in 18(66.7%) patients, heroine in 6(22.2%) and cocaine in 3(11.1%) and 24(88.8%) patients were on ongoing substance use disorder treatment. One or more comorbidities associated to COVID-19 risk were observed in 18(66.6%) of patients. During a median length of stay of 10 days (IQR:7-19), severe pneumonia developed in 7(25.9%) patients, acute respiratory distress syndrome in 5 (18.5%) and none died. Conclusion: Larger sample sizes and sero-epidemiological studies are needed to confirm the low incidence of severe COVID-19 on patients with SUD.
- 3 June 2020
- Published by Springer Nature in Journal of Public Health
- Vol. 30 (2) , 481-486
Reaching the 90–90–90 UNAIDS treatment target for people who inject drugs receiving integrated clinical care at a drug-use outpatient treatment facility
- 3 June 2020
- Published by Springer Nature in Journal of Public Health
- Vol. 30 (2) , 481-486
Reaching the 90–90–90 UNAIDS treatment target for people who inject drugs receiving integrated clinical care at a drug-use outpatient treatment facility
- 25 January 2018
- Published by Springer Nature in AIDS and Behavior
- Vol. 22 (9) , 2766-2772
Trends in AIDS Mortality, Retention in Opioid Agonist Therapy, and HIV RNA Suppression in HIV-Infected People Who Injected Drugs from 2000 to 2015
AIDS is a major cause of preventable mortality in HIV-infected people who inject drugs (HIV-PWID). An observational study was conducted to examine trends in AIDS mortality and related factors among HIV-infected individuals who died between 2000 and 2015 at an urban hospital. Overall HIV-mortality was 6.5% (413/6307) with no changes over time (p 0.76). AIDS mortality dropped in HIV-PWID (p 0.02) although it represented 26.4% at the end of study period. Age (per one-year increase) [odds ratio (OR) 0.95], third study period (2010–2015) (OR 0.54), HIV-PWID on opioid agonist therapy (OAT) (OR 0.39), and HIV RNA suppression (OR 0.15) were associated with AIDS mortality. OAT was reported in 58.3% (161/276) and RNA suppression in 30.9% (85/276) of HIV-PWID. OAT non-retention was due to drop-outs [85.2% (98/115)] and rejection [14.8% (17/115)] in HIV-PWID. Therefore, additional strategies are required to improve OAT retention and HIV RNA suppression to continue reducing AIDS mortality. El SIDA es una causa importante de mortalidad prevenible en personas infectadas por el VIH que se inyectan drogas. Se realizó un estudio observacional para examinar la tendencia en la mortalidad por SIDA y los factores relacionados a través del análisis de personas infectadas por el VIH que murieron entre 2000 y 2015 en un hospital urbano. La mortalidad general por VIH fue del 6.5% (413/6307) sin cambios a lo largo del tiempo (p 0.76). La mortalidad por SIDA disminuyó en las personas infectadas por el VIH que se inyectaban drogas (p 0.02) aunque representó el 26.4% al final del período de estudio. La edad (por cada aumento de un año) (odds ratio (OR): 0.95), el tercer período de estudio (2010-2015) (OR: 0.54), el uso de terapia con agonistas opiáceos (OR: 0.39) y la supresión del ARN del VIH (OR: 0.15) se asociaron con la mortalidad por SIDA. El uso de terapia con agonistas opiáceos se observó en el 58.3% (161/276) y la supresión del ARN en el 30.9% (85/276) de las personas infectadas por el VIH que se inyectaban drogas. El abandono en el 85.2% (98/115) y el rechazo a la terapia en el 14.8% (17/115) de las personas infectadas por el VIH que se inyectaban drogas fueron las causas para la no retención en terapia con agonistas opiáceos. Por lo tanto, se requieren estrategias adicionales para mejorar la retención en la terapia con agonistas opiáceos y la supresión del ARN para continuar reduciendo la mortalidad por SIDA.
- 25 January 2018
- Published by Springer Nature in AIDS and Behavior
- Vol. 22 (9) , 2766-2772
Trends in AIDS Mortality, Retention in Opioid Agonist Therapy, and HIV RNA Suppression in HIV-Infected People Who Injected Drugs from 2000 to 2015
AIDS is a major cause of preventable mortality in HIV-infected people who inject drugs (HIV-PWID). An observational study was conducted to examine trends in AIDS mortality and related factors among HIV-infected individuals who died between 2000 and 2015 at an urban hospital. Overall HIV-mortality was 6.5% (413/6307) with no changes over time (p 0.76). AIDS mortality dropped in HIV-PWID (p 0.02) although it represented 26.4% at the end of study period. Age (per one-year increase) [odds ratio (OR) 0.95], third study period (2010–2015) (OR 0.54), HIV-PWID on opioid agonist therapy (OAT) (OR 0.39), and HIV RNA suppression (OR 0.15) were associated with AIDS mortality. OAT was reported in 58.3% (161/276) and RNA suppression in 30.9% (85/276) of HIV-PWID. OAT non-retention was due to drop-outs [85.2% (98/115)] and rejection [14.8% (17/115)] in HIV-PWID. Therefore, additional strategies are required to improve OAT retention and HIV RNA suppression to continue reducing AIDS mortality. El SIDA es una causa importante de mortalidad prevenible en personas infectadas por el VIH que se inyectan drogas. Se realizó un estudio observacional para examinar la tendencia en la mortalidad por SIDA y los factores relacionados a través del análisis de personas infectadas por el VIH que murieron entre 2000 y 2015 en un hospital urbano. La mortalidad general por VIH fue del 6.5% (413/6307) sin cambios a lo largo del tiempo (p 0.76). La mortalidad por SIDA disminuyó en las personas infectadas por el VIH que se inyectaban drogas (p 0.02) aunque representó el 26.4% al final del período de estudio. La edad (por cada aumento de un año) (odds ratio (OR): 0.95), el tercer período de estudio (2010-2015) (OR: 0.54), el uso de terapia con agonistas opiáceos (OR: 0.39) y la supresión del ARN del VIH (OR: 0.15) se asociaron con la mortalidad por SIDA. El uso de terapia con agonistas opiáceos se observó en el 58.3% (161/276) y la supresión del ARN en el 30.9% (85/276) de las personas infectadas por el VIH que se inyectaban drogas. El abandono en el 85.2% (98/115) y el rechazo a la terapia en el 14.8% (17/115) de las personas infectadas por el VIH que se inyectaban drogas fueron las causas para la no retención en terapia con agonistas opiáceos. Por lo tanto, se requieren estrategias adicionales para mejorar la retención en la terapia con agonistas opiáceos y la supresión del ARN para continuar reduciendo la mortalidad por SIDA.
- 1 January 2018
- Published by SAGE Publications in Substance Abuse
- Vol. 39 (1) , 46-51
Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors
Background: Observational studies have reported a high prevalence of obesity and diabetes in subjects on methadone therapy; there are, however, limited data about metabolic syndrome. The aim of the study was to evaluate the prevalence of metabolic syndrome and related factors in individuals with heroin use disorder on methadone therapy. Methods: A cross-sectional study in individuals with heroin use disorder on methadone therapy at a drug abuse outpatient center. Medical examinations and laboratory analyses after a 12-hour overnight fast were recorded. Metabolic syndrome was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria. Results: One hundred and twenty-two subjects were included, with a mean age of 46.1 ± 9 years, a median body mass index (BMI) of 25.3 kg/m2 (interquartile range [IQR]: 21.2–28), and 77.9% were men. Median exposure to methadone therapy was 13 years (IQR: 5–20). Overweight and obesity were present in 29.5% and 17.2% of the participants, respectively. Metabolic syndrome components were low high-density lipoprotein (HDL) cholesterol (51.6%), hypertriglyceridemia (36.8%), high blood pressure (36.8%), abdominal obesity (27.0%), and raised blood glucose levels (18.0%). Abdominal obesity was more prevalent in women (52% vs. 20%, P = >0.01) and high blood pressure more prevalent in men (41.1% vs. 22.2%, P = .07). Prevalence of metabolic syndrome was 29.5% (95% confidence interval [CI]: 16.6–31.8). In the multivariate logistic regression analysis, BMI (per 1 kg/m2 increase odds ratio [OR]: 1.49, 95% CI: 1.27–1.76) and exposure time to methadone therapy (per 5 years of treatment increase OR: 1.38, 95% CI: 1.28–1.48) were associated with metabolic syndrome. Conclusions: Overweight and metabolic syndrome are prevalent findings in individuals with heroin use disorder on methadone therapy. Of specific concern is the association of methadone exposure with metabolic syndrome. Preventive measures and clinical routine screening should be recommended to prevent metabolic syndrome in subjects on methadone therapy.
- 1 January 2018
- Published by SAGE Publications in Substance Abuse
- Vol. 39 (1) , 46-51
Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors
Background: Observational studies have reported a high prevalence of obesity and diabetes in subjects on methadone therapy; there are, however, limited data about metabolic syndrome. The aim of the study was to evaluate the prevalence of metabolic syndrome and related factors in individuals with heroin use disorder on methadone therapy. Methods: A cross-sectional study in individuals with heroin use disorder on methadone therapy at a drug abuse outpatient center. Medical examinations and laboratory analyses after a 12-hour overnight fast were recorded. Metabolic syndrome was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria. Results: One hundred and twenty-two subjects were included, with a mean age of 46.1 ± 9 years, a median body mass index (BMI) of 25.3 kg/m2 (interquartile range [IQR]: 21.2–28), and 77.9% were men. Median exposure to methadone therapy was 13 years (IQR: 5–20). Overweight and obesity were present in 29.5% and 17.2% of the participants, respectively. Metabolic syndrome components were low high-density lipoprotein (HDL) cholesterol (51.6%), hypertriglyceridemia (36.8%), high blood pressure (36.8%), abdominal obesity (27.0%), and raised blood glucose levels (18.0%). Abdominal obesity was more prevalent in women (52% vs. 20%, P = >0.01) and high blood pressure more prevalent in men (41.1% vs. 22.2%, P = .07). Prevalence of metabolic syndrome was 29.5% (95% confidence interval [CI]: 16.6–31.8). In the multivariate logistic regression analysis, BMI (per 1 kg/m2 increase odds ratio [OR]: 1.49, 95% CI: 1.27–1.76) and exposure time to methadone therapy (per 5 years of treatment increase OR: 1.38, 95% CI: 1.28–1.48) were associated with metabolic syndrome. Conclusions: Overweight and metabolic syndrome are prevalent findings in individuals with heroin use disorder on methadone therapy. Of specific concern is the association of methadone exposure with metabolic syndrome. Preventive measures and clinical routine screening should be recommended to prevent metabolic syndrome in subjects on methadone therapy.
- 1 October 2015
- Published by Springer Nature in AIDS and Behavior
- Vol. 20 (5) , 1068-1075
Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center
Continuous HIV treatment is necessary to ensure successful combined antiretroviral therapy (cART). The aim of this study was to evaluate the incidence of patient-initiated non-structured treatment interruptions in HIV-infected persons who inject drugs and who received a multidisciplinary comprehensive program, including medical HIV care, drug-dependence treatment and psychosocial support, at a drug outpatient addiction center. Non-structured treatment interruptions were defined as ≥30 consecutive days off cART without medical indication. During a median follow-up of 53.8 months, 37/132 (28 %) patients experienced the first non-structured treatment interruptions. The cumulative probability of cART interruption at 5 years was 31.2 % (95 % CI 22.4–40.0). Current drug use injection ≥1/day (HR 14.77; 95 % CI 5.90–36.96) and cART naive patients (HR 0.35, 95 % CI 0.14–0.93) were predictive factors for non-structured treatment interruptions. HIV care provided at a drug addiction center is a useful strategy to sustain continuous cART, however, drug abstinence is essential for the long-term maintenance of cART.
- 1 October 2015
- Published by Springer Nature in AIDS and Behavior
- Vol. 20 (5) , 1068-1075
Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center
Continuous HIV treatment is necessary to ensure successful combined antiretroviral therapy (cART). The aim of this study was to evaluate the incidence of patient-initiated non-structured treatment interruptions in HIV-infected persons who inject drugs and who received a multidisciplinary comprehensive program, including medical HIV care, drug-dependence treatment and psychosocial support, at a drug outpatient addiction center. Non-structured treatment interruptions were defined as ≥30 consecutive days off cART without medical indication. During a median follow-up of 53.8 months, 37/132 (28 %) patients experienced the first non-structured treatment interruptions. The cumulative probability of cART interruption at 5 years was 31.2 % (95 % CI 22.4–40.0). Current drug use injection ≥1/day (HR 14.77; 95 % CI 5.90–36.96) and cART naive patients (HR 0.35, 95 % CI 0.14–0.93) were predictive factors for non-structured treatment interruptions. HIV care provided at a drug addiction center is a useful strategy to sustain continuous cART, however, drug abstinence is essential for the long-term maintenance of cART.
- Open Access
- 1 March 2014
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 1 (1) , ofu010
Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era
Background. Antiretroviral therapy (ART) has reduced the rates and changed the causes of hospital admission. However, human immunodeficiency virus-positive intravenous drug users (HIV-IDU) continue to have increased hospitalizations and discharge diagnosis are less defined in the late ART era. Our aim was to examine ART use, HIV-1 RNA suppression, and hospital discharge diagnoses among HIV-IDU admitted to an urban hospital.
- 1 March 2014
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 1 (1) , ofu010
Open AccessAntiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era
Background. Antiretroviral therapy (ART) has reduced the rates and changed the causes of hospital admission. However, human immunodeficiency virus-positive intravenous drug users (HIV-IDU) continue to have increased hospitalizations and discharge diagnosis are less defined in the late ART era. Our aim was to examine ART use, HIV-1 RNA suppression, and hospital discharge diagnoses among HIV-IDU admitted to an urban hospital.